Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains the impact of socioeconomic status on the management of atopic dermatitis in the clinical setting.
The prevalence of atopic dermatitis (AD) is proportionally higher in Black children and socioeconomic-related factors have been considered to play a large mediating role in the development and management of the disease in the clinical setting for this population, said Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center.
Transcript
Diversity has been cited as a major issue in dermatology clinical trials. Can you discuss challenges that contribute to these disparities and potential solutions?
That's a great question. The prevalence of AD is proportionally higher in African American children. We don't really know why that is, it may be because their access to medications, their access to specialty care is more limited. Also, family support can play a giant role in that. Having lots of other children or child care issues can play a role because AD is a very labor intensive disease, especially when you're talking about topical therapy. Transportation, there's all kinds of issues that get in the way of taking care of children who are of limited socioeconomic status.
So, in my practice, about 60% of my patients are Medicaid insured, about 50% of children in the global population are [on] Medicaid insurance. So, again, lack of access to different medications with limited insurance formularies and lack of access to subspecialty care, I think play a major role in that health care disparity. We don't know if there's anything intrinsic about African American or Black skin. We know that the barrier function tends to be a little bit better compared with White skin if you're just looking at parameters like transepidermal water loss after tape stripping, but we don't have a really good idea after that.
We also know that African American children are more susceptible to certain kinds of infections like tinea, for example. That's not one that I mentioned with their relative cutaneous energy, but that's one that can be pretty widespread in children who have AD, and occult tinea capitis is almost endemic in the urban African American population.
I was talking to a caregiver the other day about an African American patient of mine, just trying to get a handle on issues related to poor adherence or why this child has such bad disease. And they were taken care of in a clinical setting where they had been attending primary care visits, but they had a different practitioner every time because it was in a clinical setting. But without much even for that particular family in the way of no shows, we do know that poor adherence to attending clinic visits is higher in the population with low socioeconomic status.
So, all of these things make it much harder to take care of children in that patient population. And so it's not necessarily what their Fitzpatrick skin type is or having dark skin, but socioeconomic status plays a giant role.
I think to help that it would be very useful to be able to have access to social workers and case managers to just help people get to their appointments, remember their appointments, and get access to their medications when they can't get access otherwise. It's very time consuming and difficult for parents of children with moderate to severe disease who have lower health literacy and then a lot of other limitations to access to care and access to medications.
Hospitals Report Declining Cash Reserves, Increasing Reimbursement Delays and Denials
December 1st 2023A new report highlighting the twin pressures hospitals have faced over the last 18 months shows that as reimbursement delays and denials increased and cash and investments decreased, operating expenses have risen sharply.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More